DAXX, ATRX, and MSI in PanNET and Their Metastases: Correlation with Histopathological Data and Prognosis

Gisder D.M.a· Overheu O.Keller J.a· Nöpel-Dünnebacke S.b· Uhl W.c· Reinacher-Schick A.b· Tannapfel A.a· Tischoff I.a

Author affiliations

aInstitute of Pathology, Ruhr Universität Bochum, Bochum, Germany
bDepartment of Haematology and Oncology with Palliative Care, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany
cKatholisches Klinikum Bochum gGmbH, Institute of General and Visceral Surgery, St. Josef-Hospital, Bochum, Germany

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud Rent for 48h to view Buy Cloud Access for unlimited viewing via different devices Synchronizing in the ReadCube Cloud Printing and saving restrictions apply Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Abstract of Research Article

Received: June 24, 2021
Accepted: May 01, 2022
Published online: June 10, 2022

Number of Print Pages: 10
Number of Figures: 4
Number of Tables: 2

ISSN: 1015-2008 (Print)
eISSN: 1423-0291 (Online)

For additional information: https://www.karger.com/PAT

Abstract

Introduction: Studies on pancreatic neuroendocrine tumors (PanNETs) regarding loss of ATRX, DAXX, or frequency of microsatellite instability (MSI) show inconclusive results. So far, data on corresponding metastaseshave not been published. Methods: We performed immunohistochemistry (IHC) of ATRX, DAXX, MSH2, MSH6, MLH1, and PMS2 on 74 PanNETs and 19 metastases. ATRX- and DAXX-negative PanNETs were further sequenced for mutations. We used polymerase chain reaction for MSI on cases with IHC loss of MSH2, MSH6, MLH1, and PMS2. Results: Immunohistochemical loss of DAXX and ATRX was observed in 8/74 (11%) and 6/74 (8%) PanNETs. Loss of DAXX immunoreactivity was statistically associated with higher tumor grade and showed a tendency toward a decreased overall survival. Sequencing of DAXX- (7/11 [64%]) and ATRX-negative (5/11 [45%]) PanNETs revealed a mutation in 6/7 (86%) and 2/5 (40%). The specificity of immunohistochemical loss of DAXX and ATRX for mutation was 80% and 67%, respectively. The expression status of DAXX compared to primary tumor differs in 2/12 (17%) lymph node metastases. We further identified 3/74 (4%) tumors as MSI, associated with a poor prognosis. Discussion/Conclusion: Our study supports the hypothesis that a loss of DAXX immunoreactivity can identify a more aggressive subtype of PanNET with high confidence, while ATRX loss is a weaker indicator. Our results also strengthen the role of DAXX immunolabeling as a prognostic marker. We could show that ATRX might be less suitable as a surrogate for sequencing. Our results indicate that IHC of DAXX and ATRX may identify PanNET subtypes as targets for more aggressive therapy.

© 2022 S. Karger AG, Basel

References Matsukuma KE. Neuroendocrine tumors of the pancreas. Pathobiology of human disease. A dynamic encyclopedia of disease mechanisms. Elsevier Science. 2014:2284–92. Fraenkel M, Faggiano A, Valk GD. Epidemiology of neuroendocrine tumors. Front Horm Res. 2015;44:1–23. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727–33. Genus T, Bouvier C, Wong K, Srirajaskanthan R, Rous B, Talbot D, et al. Incidence and prevalence of neuroendocrine tumours in England. Endocr Abstr. 2017;52. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42. Pape U, Berndt U, Müller-Nordhorn J, Böhmig M, Roll S, Koch M, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008;15(4):1083–97. Hochwald S, Zee S, Conlon KC, Colleoni R, Louie O, Brennan M, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20:2633–42. Souche R, Coignac A, Dupuy M, Bertrand M, Raingeart I, Guiu B, et al. Outcome after pancreatectomy for neuroendocrine neoplams according to the WHO 2017 grading system: a retrospective multicentric analysis of 138 consecutive patients. Clin Res Hepatol Gastroenterol. 2020;44(3):286–94. Basturk O, Yang Z, Tang L, Hruban R, Adsay V, McCall C, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015;39(5):683–90. Tang LH, Basturk O, Sue JJ, Klimstra DS. A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol. 2016;40(9):1192–202. Schindl M, Kaczirek K, Kaserer K, Niederle B. Is the new classification of neuroendocrine pancreatic tumors of clinical help? World J Surg. 2000;24(11):1312–8. Konukiewitz B, Schlitter A, Jesinghaus M, Pfister D, Steiger K, Segler A, et al. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20. Mod Pathol. 2017;30(4):587–98. Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L, et al. The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology. 2016;104(1):85–93. Rindi G, Klersy C, Albarello L, Baudin E, Bianchi A, Buchler M, et al. Competitive testing of the WHO 2010 versus the WHO 2017 grading of pancreatic neuroendocrine neoplasms: data from a large international cohort study. Neuroendocrinology. 2019;107(4):375–86. Karnik S, Hughes C, Gu X, Rozenblatt-Rosen O, McLean G, Xiong Y, et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci U S A. 2005;102(41):14659–64. Heaphy C, De Wilde R, Jiao Y, Klein A, Edil B, Shi C, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science. 2011;333(6041):425. De Wilde R, Heaphy C, Maitra A, Meeker A, Edil B, Wolfgang C, et al. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. Mod Pathol. 2012;25(7):1033–9. Jiao Y, Shi C, Edil B, De Wilde R, Klimstra D, Maitra A, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199–203. Fishbein L, Nathanson KL. Inherited and somatic genetics of pancreatic neuroendocrine tumors. Management of pancreatic neuroendocrine tumors. New York: Springer; 2014. p. 9–32. Watson L, Solomon L, Li J, Jiang Y, Edwards M, Shin-Ya K, et al. Atrx deficiency induces telomere dysfunction, endocrine defects, and reduced life span. J Clin Invest. 2013;123(5):2049–63. Pea A, Yu J, Marchionni L, Noe M, Luchini C, Pulvirenti A, et al. Genetic analysis of small well-differentiated pancreatic neuroendocrine tumors identifies subgroups with differing risks of liver metastases. Ann Surg. 2020;271(3):566–73. Marinoni I, Schmitt AM, Di Domenico A, Perren A. Genomic landscape in gastroenteropancreatic neuroendocrine neoplasms and its usefulness in improving the prognostic evaluation. Diagn Histopathology. 2018;24(3):111–9. Lewis PW, Elsaesser SJ, Noh KM, Stadler SC, Allis CD. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci U S A. 2010;107(32):14075–80. Scarpa A, Chang D, Nones K, Corbo V, Patch A, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65–71. Chan C, Laddha S, Lewis P, Koletsky M, Robzyk K, Da Silva E, et al. ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun. 2018;9(1):1–10. Loeb LA. A mutator phenotype in cancer. Cancer Res. 2001;61(8):3230–9. Kunkel TA, Erie DA. DNA mismatch repair. Annu Rev Biochem. 2005;74:681–710. Meyers M, Hwang A, Wagner M, Boothman D. Role of DNA mismatch repair in apoptotic responses to therapeutic agents. Environ Mol Mutagen. 2004;44(4):249–64. Arnold C, Nagasaka T, Goel A, Scharf I, Grabowski P, Sosnowski A, et al. Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors. Int J Cancer. 2008;123(7):1556–64. Sameer AS, Nissar S, Fatima K. Mismatch repair pathway: molecules, functions, and role in colorectal carcinogenesis. Eur J Cancer Prev. 2014;23(4):246–57. Müller C, Schulmann K, Reinacher-Schick A, Andre N, Arnold D, Tannapfel A, et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis. 2008;23(11):1033–9. House M, Herman J, Guo M, Hooker C, Schulick R, Cameron J, et al. Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms. Surgery. 2003;134(6):902–8. Arnason T, Sapp H, Rayson D, Barnes P, Drewniak M, Nassar B, et al. Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors. Arch Pathol Lab Med. 2011;135(12):1539–44. Mei M, Deng D, Liu T, Sang X, Lu X, Xiang H, et al. Clinical implications of microsatellite instability and MLH1 gene inactivation in sporadic insulinomas. J Clin Endocrinol Metab. 2009;94(9):3448–57. Arnold CN, Sosnowski A, Schmitt-Gräff A, Arnold R, Blum HE. Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system. Int J Cancer. 2007;120(10):2157–64. Liu IH, Ford JM, Kunz PL. DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications. Cancer Treat Rev. 2016;44:1–9. Nakata B, Wang Y, Yashiro M, Nishioka N, Tanaka H, Ohira M, et al. Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin Cancer Res. 2002;8(8):2536–40. Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72. Chou A, Itchins M, de Reuver P, Arena J, Clarkson A, Sheen A, et al. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors. Hum Pathol. 2018;82:249–57. Hechtman JF, Klimstra DS, Nanjangud G, Frosina D, Shia J, Jungbluth AA. Performance of DAXX immunohistochemistry as a screen for DAXX mutations in pancreatic neuroendocrine tumors. Pancreas. 2019;48(3):396–9. Marinoni I, Kurrer A, Vassella E, Dettmer M, Rudolph T, Banz V, et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 2014;146(2):453–60. Singhi A, Liu T, Roncaioli J, Cao D, Zeh H, Zureikat A, et al. Alternative lengthening of telomeres and loss of DAXX/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors. Clin Cancer Res. 2017;23(2):600–9. Park JK, Paik WH, Lee K, Ryu JK, Lee SH, Kim YT. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors. Oncotarget. 2017;8(30):49796–806. VandenBussche C, Allison D, Graham M, Charu V, Lennon A, Wolfgang C, et al. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. Cancer Cytopathol. 2017;125(7):544–51. Pipinikas C, Dibra H, Karpathakis A, Feber A, Novelli M, Oukrif D, et al. Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2015;22(3):13–8. Hackeng W, Brosens L, Kim J, O’Sullivan R, Sung Y, Liu T, et al. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut. 2022 May;71(5):961–73. Kim J, Brosnan-Cashman J, An S, Kim S, Song K, Kim M, et al. Alternative lengthening of telomeres in primary pancreatic neuroendocrine tumors is associated with aggressive clinical behavior and poor survival. Clin Cancer Res. 2017;23(6):1598–606. Manley BJ, Hakimi AA. Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact. Curr Opin Urol. 2016;26(5):383–7. Li Z, Hao P, Wu Q, Li F, Zhao J, Wu K, et al. Genetic mutations associated with metastatic clear cell renal cell carcinoma. Oncotarget. 2016;7(13):16172–9. Baldus SE, Schaefer KL, Engers R, Hartleb D, D, Gabbert HE, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010;16(3):790–9. Cives M, Partelli S, Palmirotta R, Palmirotta R, Lovero D, Mandriani B, et al. DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. Sci Rep. 2019;9(1):1–10. Yamamichi A, Ohka F, Aoki K, Suzuki H, Kato A, Hirano M, et al. Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion. Brain Tumor Pathol. 2018;35(2):106–13. Purkait S, Miller C, Kumar A, Sharma V, Pathak P, Jha P, et al. ATRX in diffuse gliomas with its mosaic/heterogeneous expression in a subset. Brain Pathol. 2017;27(2):138–45. Kunstmann E, Vieland J, Brasch F, Hahn S, Epplen J, Schulmann K, et al. HNPCC: six new pathogenic mutations. BMC Med Genet. 2004;5:16. Stefansson I, Akslen L, MacDonald N, Ryan A, Das S, Jacobs I, et al. Is frequent in sporadic endometrial carcinomas with microsatellite loss of hMSH2 and hMSH6 expression instability. Clin Cancer Res. 2002;8(1):138–43. Wu Y, Berends M, Mensink R, Kempinga C, Sijmons R, Van Der Zee A, et al. Association of hereditary nonpolyposis colorectal cancer: related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet. 1999;65(5):1291–8. Article / Publication Details

First-Page Preview

Abstract of Research Article

Received: June 24, 2021
Accepted: May 01, 2022
Published online: June 10, 2022

Number of Print Pages: 10
Number of Figures: 4
Number of Tables: 2

ISSN: 1015-2008 (Print)
eISSN: 1423-0291 (Online)

For additional information: https://www.karger.com/PAT

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

留言 (0)

沒有登入
gif